絞り込み

16641

広告

「"Cohen AT "[Author]」の検索結果

242件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Predicting atrial fibrillation in primary care using machine learning.

Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database.

Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals.

Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial.

Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.

Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis.

Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial.

Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom.

Rivaroxaban and the EINSTEIN clinical trial programme.

Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study.

Anticoagulant Selection for Patients with VTE-Evidence from A Systematic Literature Review of Network Meta-analyses.

Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study.

Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients.

Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.

Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.

Magnitude of venous thromboembolism risk in US hospitals: impact of evolving national guidelines for prevention of venous thromboembolism.

Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.

Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis.

Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります